**DESCRIPTION**

*Drug Metabolism and Pharmacokinetics* (DMPK) is an official online journal of the *Japanese Society for the Study of Xenobiotics* (JSSX) and the *International Society for the Study of Xenobiotics* (ISSX), and it replaces the JSSX’s former journal, Xenobiotic Metabolism and Disposition. The journal will accept original submissions in English on the understanding that the work is unpublished and is not being considered for publication elsewhere.

**Scope of submitted manuscripts**

DMPK publishes original and innovative scientific papers that address topics broadly related to xenobiotics. The term xenobiotic includes medicinal as well as environmental and agricultural chemicals and macromolecules. The journal is organized into sections as follows:

- Drug metabolism / Biotransformation
- Pharmacokinetics and pharmacodynamics
- Toxicokinetics and toxicodynamics
- Drug-drug interaction / Drug-food interaction
- Mechanism of drug absorption and disposition (including transporter)
- Drug delivery system
- Clinical pharmacy and pharmacology
- Analytical method
- Factors affecting drug metabolism and transport
- Expression of genes for drug-metabolizing enzymes and transporters
- Pharmacogenetics and pharmacogenomics
- Pharmacoepidemiology

**IMPACT FACTOR**

2022: 2.100 © Clarivate Analytics Journal Citation Reports 2023

**ABSTRACTING AND INDEXING**

Scopus
Science Citation Index Expanded
BIOSIS Previews
PubMed/Medline
EDITORIAL BOARD

Editor-in-Chief
Kouichi Yoshinari, University of Shizuoka, Japan

Associate Editors
Koji Chiba, Yokohama University of Pharmacy, Japan
Young-Jin Chun, Chung-Ang University, Korea
Hideki Hirabayashi, Takeda Pharmaceutical Company Limited, Japan
Masahiro Hiratsuka, Tohoku University, Japan
Takushi Kanazu, Shionog and Co Ltd, Japan
Takafumi Komori, Eisai Co Ltd, Japan
John Miners, Flinders University, Australia
Takeo Nakanishi, Takasaki University of Health and Welfare, Japan
Masayo Oishi, Astellas Pharma Inc, Japan
Masataka Oitate, Daichi Sankyo Co Ltd Shinagawa R and D Center, Japan
Takashi Okura, Teikyo University, Japan
Takahiko Tanigawa, Bayer Yakuhihki Kaisha, Japan
Geoffrey Tucker, The University of Sheffield, United Kingdom
Satoshi Yamaori, Tokyo University of Pharmacy and Life Sciences, Japan

Former Editors-in-Chief
Kan Chiba
Masahiro Hayashi
Ikumi Tamai
Hiroshi Yamazaki

Editorial Advisory Board
Shin-ichi Akanuma
Adithan Chandrasekaran
Varanuj Chatsudthipong
Yoshiharu Deguchi
Ryoichi Fujiwara
Tatsuki Fukami
Eiichi Fuse
Hyo-Kyung Han
 Nobumitsu Hanioka
Takeshi Hirota
Masakiyo Hosokawa
Shin-ichi Ikushiro
Katsuhisa Inoue
Tatsuhiro Ishida
Naoki Ishiguro
Yuji Ishii
Kiyomi Ito
Kousei Ito
Kaoru Kobayashi
Yoshiyuki Kubo
Toshiyuki Kume
Kazuya Maeda
Yasuhiro Masubuchi
Tamihide Matsunaga
Toshiya Moriwaki
Norie Murayama
Taisei Mushiroma
Naomi Nagai
Miki Nakajima
Yoichi Naritomi
Shingo Oda
Takuo Ogihara
Kenichiro Ogura
Tomoyuki Ohe
Sumio Ohtsuki
Shogo Ozawa
Amin Rostami-Hodjegan
Kimie Sai
Seigo Sanoh
Yoshiyuki Shirasaka
Kazumi Sugihara
Masanori Tachikawa
Hideo Takakusa
Ikumi Tamai
Wichitra Tassaneeyakul
Tomohiro Terada
Masahiro Tohkin
Masatoshi Tomi
Yasuo Uchida
Yune-Fang Ueng
Yoshitaka Yamaguchi
Hiroshi Yamazaki
Bingfang Yan
Ikuko Yano
GUIDE FOR AUTHORS

Please be informed that a manuscript handling fee is charged for submissions from non-JSSX/ISSX members from 15 December 2017.

Manuscript handling fees
Authors are requested to pay a manuscript handling fee (the amount equivalent to the annual membership fee of JSSX) within 2 weeks. Submissions will only be considered after payment of the manuscript handling fee. The guidance of the payment of a manuscript handling fee will be informed by an email from the society secretariat. Please pay by a credit card. The manuscript handling fee is non-refundable and a paper may be rejected by the Editors without being sent for review, should a paper be inconsistent with the Aims and Scope of the Journal as set out on the Journal website, or not adhere to the style requirements as outlined in the Guide for Authors. The manuscript handling fees are used to support journal related activities.

Members of JSSX and ISSX are eligible for a manuscript handling fee waiver. If you request a waiver, please indicate it in the Copyright Transfer Form.

For more details about a manuscript handling fee, please contact the JSSX's secretariat (maf-jssx@mynavi.jp).

BEFORE YOU BEGIN

Ethics in publishing
Please see our information on Ethics in publishing.

Policy and ethics
The cover letter must contain a statement assuring that the material has not been published or is not under active consideration by another journal. The authors must also indicate in the cover letter that the research was conducted in accordance with the Declaration of Helsinki and/or with the Guide for the Care and Use of Laboratory Animals as adopted and promulgated by the United States National Institutes of Health.

Declaration of interest
All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence (bias) their work. Examples of potential competing interests include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding. Authors must disclose any interests in two places: 1. A summary declaration of interest statement in the title page file (if double anonymized) or the manuscript file (if single anonymized). If there are no interests to declare then please state this: 'Declarations of interest: none'. 2. Detailed disclosures as part of a separate Declaration of Interest form, which forms part of the journal's official records. It is important for potential interests to be declared in both places and that the information matches. More information.

Declaration of generative AI in scientific writing
The below guidance only refers to the writing process, and not to the use of AI tools to analyse and draw insights from data as part of the research process.

Where authors use generative artificial intelligence (AI) and AI-assisted technologies in the writing process, authors should only use these technologies to improve readability and language. Applying the technology should be done with human oversight and control, and authors should carefully review and edit the result, as AI can generate authoritative-sounding output that can be incorrect, incomplete or biased. AI and AI-assisted technologies should not be listed as an author or co-author, or be cited as an author. Authorship implies responsibilities and tasks that can only be attributed to and performed by humans, as outlined in Elsevier’s AI policy for authors.

Authors should disclose in their manuscript the use of AI and AI-assisted technologies in the writing process by following the instructions below. A statement will appear in the published work. Please note that authors are ultimately responsible and accountable for the contents of the work.

Disclosure instructions
Authors must disclose the use of generative AI and AI-assisted technologies in the writing process by adding a statement at the end of their manuscript in the core manuscript file, before the References list. The statement should be placed in a new section entitled ‘Declaration of Generative AI and AI-assisted technologies in the writing process’.

Statement: During the preparation of this work the author(s) used [NAME TOOL / SERVICE] in order to [REASON]. After using this tool/service, the author(s) reviewed and edited the content as needed and take(s) full responsibility for the content of the publication.

This declaration does not apply to the use of basic tools for checking grammar, spelling, references etc. If there is nothing to disclose, there is no need to add a statement.

Submission declaration and verification
Submission of an article implies that the work described has not been published previously (except in the form of an abstract, a published lecture or academic thesis, see 'Multiple, redundant or concurrent publication' for more information), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language, including electronically without the written consent of the copyright-holder. To verify compliance, your article may be checked by Crossref Similarity Check and other originality or duplicate checking software.

Submission declaration and verification
Submission of an article implies that the work described has not been published previously (except in the form of an abstract or as part of a published lecture or academic thesis or as an electronic preprint, see https://www.elsevier.com/sharingpolicy), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language, including electronically without the written consent of the copyright-holder.

Plagiarism
All DMPK submissions will be subjected to plagiarism evaluation using the software of iThenticate/Crosscheck prior to editorial processing. Manuscripts that cannot pass the plagiarism evaluation pre-screening will be automatically rejected without review and the plagiarism evaluation will not be provided to authors. For more information, please go to: https://www.elsevier.com/editors/perk/plagiarism-detection. Author plagiarism will be reported to the subject institution(s) and funder(s).

Preprints
Please note that preprints can be shared anywhere at any time, in line with Elsevier's sharing policy. Sharing your preprints e.g. on a preprint server will not count as prior publication (see 'Multiple, redundant or concurrent publication' for more information).

Use of inclusive language
Inclusive language acknowledges diversity, conveys respect to all people, is sensitive to differences, and promotes equal opportunities. Content should make no assumptions about the beliefs or commitments of any reader; contain nothing which might imply that one individual is superior to another on the grounds of age, gender, race, ethnicity, culture, sexual orientation, disability or health condition; and use inclusive language throughout. Authors should ensure that writing is free from bias, stereotypes, slang, reference to dominant culture and/or cultural assumptions. We advise to seek gender neutrality by using plural nouns ("clinicians, patients/clients") as default/wherever possible to avoid using "he, she," or "he/she." We recommend avoiding the use of descriptors that refer to personal attributes such as age, gender, race, ethnicity, culture, sexual orientation, disability or health condition unless they are relevant and valid. When coding terminology is used, we recommend to avoid offensive or exclusionary terms such as "master", "slave", "blacklist" and "whitelist". We suggest using alternatives that are more appropriate and (self-) explanatory such as "primary", "secondary", "blocklist" and "allowlist". These guidelines are meant as a point of reference to help identify appropriate language but are by no means exhaustive or definitive.
Contributors
Each author is required to declare their individual contribution to the article: all authors must have materially participated in the research and/or article preparation, so roles for all authors should be described. The statement that all authors have approved the final article should be true and included in the disclosure.

Changes to authorship
Authors are expected to consider carefully the list and order of authors before submitting their manuscript and provide the definitive list of authors at the time of the original submission. Any addition, deletion or rearrangement of author names in the authorship list should be made only before the manuscript has been accepted and only if approved by the journal Editor. To request such a change, the Editor must receive the following from the corresponding author: (a) the reason for the change in author list and (b) written confirmation (e-mail, letter) from all authors that they agree with the addition, removal or rearrangement. In the case of addition or removal of authors, this includes confirmation from the author being added or removed. Only in exceptional circumstances will the Editor consider the addition, deletion or rearrangement of authors after the manuscript has been accepted. While the Editor considers the request, publication of the manuscript will be suspended. If the manuscript has already been published in an online issue, any requests approved by the Editor will result in a corrigendum.

Article transfer service
This journal is part of our Article Transfer Service. This means that if the Editor feels your article is more suitable in one of our other participating journals, then you may be asked to consider transferring the article to one of those. If you agree, your article will be transferred automatically on your behalf with no need to reformat. Please note that your article will be reviewed again by the new journal. More information.

Author Contributions
To be included as an author of a submission an individual must have made substantive and definable intellectual contributions to the submitted work and be able to take public responsibility for appropriate portions of the work. Authorship is not justified for the acquisition of funding, provision of research materials, data generation or provision of space. Individuals involved in making such contributions should be listed under Acknowledgments.

Elsevier supports responsible sharing
Find out how you can share your research published in Elsevier journals.

Role of the funding source
You are requested to identify who provided financial support for the conduct of the research and/or preparation of the article and to briefly describe the role of the sponsor(s), if any, in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. If the funding source(s) had no such involvement, it is recommended to state this.

Open access
Please visit our Open Access page for more information about open access publishing in this journal. This journal offers authors a choice in publishing their research:

Open Access
• Articles are freely available to both subscribers and the wider public with permitted reuse
• An Open Access publication fee is payable by authors or their research funder

Subscription
• Articles are made available to subscribers as well as developing countries and patient groups through our access programs
• No Open Access publication fee

All articles published Open Access will be immediately and permanently free for everyone to read and download. Permitted reuse is defined by your choice of one of the following Creative Commons user licenses:
Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND): for non-commercial purposes, lets others distribute and copy the article, and to include in a collective work (such as an anthology), as long as they credit the author(s) and provided they do not alter or modify the article.

To provide Open Access, this journal has a publication fee which needs to be met by the authors or their research funders for each article published Open Access.

Your publication choice will have no effect on the peer review process or acceptance of submitted articles.

Language (usage and editing services)
Please write your text in good English (American or British usage is accepted, but not a mixture of these). Authors who feel their English language manuscript may require editing to eliminate possible grammatical or spelling errors and to conform to correct scientific English may wish to use the Language Editing service available from Elsevier's Language Services.

Submission
Our online submission system guides you stepwise through the process of entering your article details and uploading your files. The system converts your article files to a single PDF file used in the peer-review process. Editable files (e.g., Word, LaTeX) are required to typeset your article for final publication. All correspondence, including notification of the Editor's decision and requests for revision, is sent by e-mail.

Submit your article
For submission of articles to DMPK please go to the journal's online submission site at https://www.editorialmanager.com/dmpk.

PREPARATION
Language
DMPK is committed to the publication of science from its designated fields of interest, irrespective of geographical and sponsor source. The peer review process routinely conducted by the Editorial Board and expert reviewers is dedicated to constructive, collegial feedback with the aim of improving the content and clarity of submissions. The Editorial Board and its reviewers will however not undertake to provide major revisions of the grammatical content of submitted manuscripts, irrespective of the scientific merit. Accordingly, authors are advised to ensure that their manuscripts are written in clear, understandable English before submitting these to the journal. American or British usage is accepted, but not a mixture of these.

Queries
For questions about the editorial process (including the status of manuscripts under review) or for technical support on submissions, please visit our Support Center.

Peer review
This journal operates a single anonymized review process. All contributions will be initially assessed by the editor for suitability for the journal. Papers deemed suitable are then typically sent to a minimum of two independent expert reviewers to assess the scientific quality of the paper. The Editor is responsible for the final decision regarding acceptance or rejection of articles. The Editor’s decision is final. Editors are not involved in decisions about papers which they have written themselves or have been written by family members or colleagues or which relate to products or services in which the editor has an interest. Any such submission is subject to all of the journal’s usual procedures, with peer review handled independently of the relevant editor and their research groups. More information on types of peer review.

Use of Word processing Software
It is important that the file be saved in the native format of the word processor used. Reports must be written in English and include an abstract that does not exceed 200 words. Manuscript pages should be numbered sequentially and double-spaced with 1” or 25 mm margins. Size 12 (point) Times Roman or Arial font is preferred. The text should be in single-column format. Keep the layout of the text as simple as possible. Most formatting codes will be removed and replaced on processing the article. In particular, do not use the word processor's options to justify text or to hyphenate words. However, do use bold face, italics, subscripts, superscripts, etc. Do not embed "graphically designed" equations or tables, but prepare these using the word processor's facility. When preparing tables, if you are using a table grid, use only one grid for each individual table and not a grid for each row.
no grid is used, use tabs, not spaces, to align columns. The electronic text should be prepared in a way very similar to that of conventional manuscripts (see also the Guide to Publishing with Elsevier: https://www.elsevier.com/guidepublication.) Do not import the figures into the text file but, instead, indicate their approximate locations directly in the electronic text and on the manuscript. See also the section on Electronic illustrations. To avoid unnecessary errors you are strongly advised to use the "spell-check" and "grammar-check" functions of your wordprocessor.

**Type of papers**

The journal publishes Regular Articles, Notes, Reviews, White Paper and Commentary. With the exception of Reviews and White Paper, manuscripts are reviewed anonymously by at least two independent referees, whose comments will form the basis of the final decision by the editor. Review and White Paper articles are generally invited or recommended by the editorial members, and checked by one or two anonymous referees.

**Regular Articles**: New, significant, innovative, and original findings are suitable as Regular Articles. Length of the text including references (not including Abstract, tables, figures and figure legends) should not exceed 5,500 words. More than a total of eight figures and/or tables in print will not be accepted. Authors are encouraged to use Supplemental materials to show more figures and/or tables if more information is needed to support the paper's conclusions.

**Notes**: Papers containing new facts and important data derived from incomplete or partial studies may be suitable as Notes. Length of the text including references (not including Abstract, tables, figures and figure legends) should not exceed 2,000 words. More than a total of two figures and/or tables in print will not be accepted. Authors are encouraged to use Supplemental materials if more information is needed to support paper's conclusion.

**Commentaries**: Commentaries are commissioned, authoritative evidence-based and/or opinion pieces that relate principally to a specific article or articles published, generally, in the same edition of the Journal. Limited to 2500 words including references. Subtract 100 words for each illustration and 300 words for each table.

**Reviews**: Review articles are generally invited or recommended by the editorial members. Contemporary reviews on topics of interest covering the more recent aspects of a subject in the area of interest will be published. These may be critical reviews that present the authors' review of the current state of the subject or prospective articles intended to stimulate discussion and research.

**White Paper**: An authorized, official report from a public and/or academic organization(s) to present and address a complex issue in the field related to the scope of DMPK will be published as White Paper. White Paper articles are generally invited or recommended by the editorial members. If interested, you may also provide your proposal by e-mail to the Editorial Office (dmpk.editorialoffice@elsevier.com).

**Essential Title Page Information**

- **Title**: Concise and informative. Titles are often used in information-retrieval systems. Avoid abbreviations and formulae where possible.
- **Author names and affiliations**: Please indicate the family name clearly in those cases where it may not be obvious (e.g., a double name). Present the authors' affiliation addresses (where the actual work was done) below the names. Indicate all affiliations with a lower-case superscript letter immediately after the author’s name and in front of the appropriate address. Provide the full postal address for each affiliation, including the country name and the e-mail address of each author.
- **Corresponding author**: Clearly indicate who is willing to handle correspondence at all stages of refereeing and publication, also post-publication. Ensure that telephone and fax numbers (with country and area code) are provided in addition to the e-mail address and the complete postal address.
- **Present/permanent address**: If an author has moved since the work described in the article was done, or was visiting at the time, a ‘Present address’ (or ‘Permanent address’) may be indicated as a footnote to that author's name. The address at which the author actually did the work must be retained as the main, affiliation address. Superscript Arabic numerals are used for such footnotes.

**Abstract**

A concise and factual abstract of 200 or fewer words is mandatory to comply with Internet criteria for searching. The abstract should state briefly the purpose of the research, the principal results and major conclusions. An abstract is often presented separately from the article, so it must be able to
stand alone. For this reason, References should be avoided, but if essential, they must be cited in full, without reference to the reference list. Also, non-standard or uncommon abbreviations should be avoided, but if essential they must be defined at their first mention in the abstract itself.

**Graphical Abstract**
Authors are recommended supply of a graphical abstract for all types of articles if invited to submit a revision. The abstract should summarize the contents of the paper in a concise, pictorial form designed to capture the attention of a wide readership and for compilation of databases. Carefully drawn figures that serve to illustrate the theme of the paper are desired. Authors may also provide appropriate text, not exceeding 30 words. The content of the graphical abstract will be typeset and should be kept within an area of 5 cm tall by 17 cm wide (landscape shape). Authors are encouraged to limit graphical abstracts to 189 pixels tall by 642 pixels wide to ensure the image and text will be legible when displayed on-line. Authors must supply the graphic separately as an electronic file. For examples of graphical abstracts, please visit the DMPK home page of https://www.sciencedirect.com/science/journal/13474367.

**Keywords**
Immediately after the abstract, provide a list of 5 - 10 keywords, using American spelling and avoiding general and plural terms and multiple concepts (avoid, for example, 'and', 'of'). Be sparing with abbreviations: only abbreviations firmly established in the field may be eligible. These keywords will be used for indexing purposes.

**Acknowledgements**
Collate acknowledgements in a separate section at the end of the article before the references and do not, therefore, include them on the title page, as a footnote to the title or otherwise. List here those individuals who provided help during the research (e.g., providing language help, writing assistance or proof reading the article, etc.).

**Nomenclature and abbreviations**
The nomenclature used to identify receptors and ion channels should conform to guidelines of the Committee on Receptor Nomenclature and Drug Classification of the International Union of Pharmacology. These are accessible at http://www.iuphar-db.org/nomenclature.html. Use only abbreviations that are generally accepted by the scientific community. All nonstandard abbreviations and acronyms should be spelled out at the point of the first use in the Abstract and the body of the text, followed by the abbreviation in parentheses. Drugs or other xenobiotics should be identified only by their chemical or generic names. The source, including company name and location, for all chemicals, reagents, cell lines, tissue, and experimental animals must be provided in the text.

**Genbank**
DNA sequences and GenBank Accession numbers. Many Elsevier journals cite “gene accession numbers” in their running text and footnotes. Gene accession numbers refer to genes or DNA sequences about which further information can be found in the databases at the National Center for Biotechnical Information (NCBI) at the National Library of Medicine. Every accession number cited in an article should be typed in bold, underlined text. Letters in the accession number should always be capitalized. Example: a B-cell tumor from a chronic lymphatic leukemia (GenBank accession no. BE675048), and a T-cell lymphoma (GenBank accession no. AA361117)
Authors are encouraged to check accession numbers used very carefully. An error in a letter or number can result in a dead link. Note that in the final version of the electronic copy, the accession number text will be linked to the appropriate source in the NCBI databases enabling readers to go directly to that source from the article.

**Math formulae**
Please submit math equations as editable text and not as images. Present simple formulæ in line with normal text where possible and use the solidus (/) instead of a horizontal line for small fractional terms, e.g., X/Y. In principle, variables are to be presented in italics. Powers of e are often more conveniently denoted by exp. Number consecutively any equations that have to be displayed separately from the text (if referred to explicitly in the text).

**Footnotes**
Footnotes should be used sparingly. Number them consecutively throughout the article. Many word processors can build footnotes into the text, and this feature may be used. Otherwise, please indicate the position of footnotes in the text and list the footnotes themselves separately at the end of the article. Do not include footnotes in the Reference list.
**Artwork**

*Electronic artwork*

**General points**

- Make sure you use uniform lettering and sizing of your original artwork.
- Embed the used fonts if the application provides that option.
- Aim to use the following fonts in your illustrations: Arial, Courier, Times New Roman, Symbol, or use fonts that look similar.
- Number the illustrations according to their sequence in the text.
- Use a logical naming convention for your artwork files.
- Provide captions to illustrations separately.
- Size the illustrations close to the desired dimensions of the published version.
- Submit each illustration as a separate file.
- Ensure that color images are accessible to all, including those with impaired color vision.

A detailed [guide on electronic artwork](https://www.elsevier.com/locate/dmpk) is available.

**You are urged to visit this site; some excerpts from the detailed information are given here.**

**Formats**

If your electronic artwork is created in a Microsoft Office application (Word, PowerPoint, Excel) then please supply 'as is' in the native document format.

Regardless of the application used other than Microsoft Office, when your electronic artwork is finalized, please 'Save as' or convert the images to one of the following formats (note the resolution requirements for line drawings, halftones, and line/halftone combinations given below):

- EPS (or PDF): Vector drawings, embed all used fonts.
- TIFF (or JPEG): Color or grayscale photographs (halftones), keep to a minimum of 300 dpi.
- TIFF (or JPEG): Bitmapped (pure black & white pixels) line drawings, keep to a minimum of 1000 dpi.
- TIFF (or JPEG): Combinations bitmapped line/half-tone (color or grayscale), keep to a minimum of 500 dpi.

**Please do not:**

- Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); these typically have a low number of pixels and limited set of colors;
- Supply files that are too low in resolution;
- Submit graphics that are disproportionately large for the content.

Line drawings, including graphs, should be black on a white background. Lettering should be large enough to permit photographic reduction. For those not to be reduced, the format should not exceed 16x20 cm. Photographs (or halftone illustrations) must be of good quality with as much contrast as possible. The magnification of micrographs should be indicated by a scale bar in the figure. Illustrations should be numbered with Arabic numerals. The legends should be typed separately with double spacing.

**Figure captions**

Ensure that each illustration has a caption. Supply captions separately, not attached to the figure. A caption should comprise a brief title (not on the figure itself) and a description of the illustration. Keep text in the illustrations themselves to a minimum but explain all symbols and abbreviations used.

**Tables**

All tables must be numbered consecutively in Arabic numerals and cited in the text. Titles should be brief but descriptive. Tables should be compiled on separate pages, together with a legend and/or footnotes. Tables should not have vertical lines, and horizontal lines must be kept to a minimum. Be sparing in the use of tables and ensure that the data presented in tables do not duplicate results described elsewhere in the article.

**References**

**Citation in text**

Please ensure that every reference cited in the text is also present in the reference list (and vice versa). Any references cited in the abstract must be given in full. Unpublished results and personal communications are not recommended in the reference list, but may be mentioned in the text. If these references are included in the reference list they should follow the standard reference style of the journal and should include a substitution of the publication date with either 'Unpublished results' or 'Personal communication'. Citation of a reference as 'in press' implies that the item has been accepted for publication.
Reference links
Increased discoverability of research and high quality peer review are ensured by online links to the sources cited. In order to allow us to create links to abstracting and indexing services, such as Scopus, CrossRef and PubMed, please ensure that data provided in the references are correct. Please note that incorrect surnames, journal/book titles, publication year and pagination may prevent link creation. When copying references, please be careful as they may already contain errors. Use of the DOI is encouraged.

Web references
As a minimum, the full URL should be given and the date when the reference was last accessed. Any further information, if known (DOI, author names, dates, reference to a source publication, etc.), should also be given. Web references can be listed separately (e.g., after the reference list) under a different heading if desired, or can be included in the reference list.

Data references
This journal encourages you to cite underlying or relevant datasets in your manuscript by citing them in your text and including a data reference in your Reference List. Data references should include the following elements: author name(s), dataset title, data repository, version (where available), year, and global persistent identifier. Add [dataset] immediately before the reference so we can properly identify it as a data reference. The [dataset] identifier will not appear in your published article.

Preprint references
Where a preprint has subsequently become available as a peer-reviewed publication, the formal publication should be used as the reference. If there are preprints that are central to your work or that cover crucial developments in the topic, but are not yet formally published, these may be referenced. Preprints should be clearly marked as such, for example by including the word preprint, or the name of the preprint server, as part of the reference. The preprint DOI should also be provided.

References in a special issue
Please ensure that the words ‘this issue’ are added to any references in the list (and any citations in the text) to other articles in the same Special Issue.

Reference formatting
There are no strict requirements on reference formatting at submission. References can be in any style or format as long as the style is consistent. Where applicable, author(s) name(s), journal title/book title, chapter title/article title, year of publication, volume number/book chapter and the pagination must be present. Use of DOI is highly encouraged. The reference style used by the journal will be applied to the accepted article by Elsevier at the proof stage. Note that missing data will be highlighted at proof stage for the author to correct. If you do wish to format the references yourself they should be arranged according to the following examples:

Reference style
Text: Indicate references by number(s) in square brackets in line with the text. The actual authors can be referred to, but the reference number(s) must always be given.
List: Number the references (numbers in square brackets) in the list in the order in which they appear in the text.
Examples:
Reference to a journal publication:
Reference to a journal publication with an article number:
Reference to a book:
Reference to a chapter in an edited book:
Reference to a website:
Reference to a dataset:

Note shortened form for last page number. e.g., 51–9, and that for more than 6 authors the first 6 should be listed followed by 'et al.' For further details you are referred to 'Uniform Requirements for Manuscripts submitted to Biomedical Journals' (J Am Med Assoc 1997;277:927–34) (see also Samples of Formatted References).

**Journal abbreviations source**
Journal names should be abbreviated according to the List of Title Word Abbreviations.

**Video**
Elsevier accepts video material and animation sequences to support and enhance your scientific research. Authors who have video or animation files that they wish to submit with their article are strongly encouraged to include links to these within the body of the article. This can be done in the same way as a figure or table by referring to the video or animation content and noting in the body text where it should be placed. All submitted files should be properly labeled so that they directly relate to the video file's content. In order to ensure that your video or animation material is directly usable, please provide the file in one of our recommended file formats with a preferred maximum size of 150 MB per file, 1 GB in total. Video and animation files supplied will be published online in the electronic version of your article in Elsevier Web products, including ScienceDirect. Please supply 'stills' with your files: you can choose any frame from the video or animation or make a separate image. These will be used instead of standard icons and will personalize the link to your video data. For more detailed instructions please visit our video instruction pages. Note: since video and animation cannot be embedded in the print version of the journal, please provide text for both the electronic and the print version for the portions of the article that refer to this content.

**Supplementary material**
Supplementary material such as applications, images and sound clips, can be published with your article to enhance it. Submitted supplementary items are published exactly as they are received (Excel or PowerPoint files will appear as such online). Please submit your material together with the article and supply a concise, descriptive caption for each supplementary file. If you wish to make changes to supplementary material during any stage of the process, please make sure to provide an updated file. Do not annotate any corrections on a previous version. Please switch off the 'Track Changes' option in Microsoft Office files as these will appear in the published version.

**Research data**
This journal encourages and enables you to share data that supports your research publication where appropriate, and enables you to interlink the data with your published articles. Research data refers to the results of observations or experimentation that validate research findings, which may also include software, code, models, algorithms, protocols, methods and other useful materials related to the project.

Below are a number of ways in which you can associate data with your article or make a statement about the availability of your data when submitting your manuscript. If you are sharing data in one of these ways, you are encouraged to cite the data in your manuscript and reference list. Please refer to the "References" section for more information about data citation. For more information on depositing, sharing and using research data and other relevant research materials, visit the research data page.

**Data linking**
If you have made your research data available in a data repository, you can link your article directly to the dataset. Elsevier collaborates with a number of repositories to link articles on ScienceDirect with relevant repositories, giving readers access to underlying data that gives them a better understanding of the research described.

There are different ways to link your datasets to your article. When available, you can directly link your dataset to your article by providing the relevant information in the submission system. For more information, visit the database linking page.

For supported data repositories a repository banner will automatically appear next to your published article on ScienceDirect.
In addition, you can link to relevant data or entities through identifiers within the text of your manuscript, using the following format: Database: xxxx (e.g., TAIR: AT1G01020; CCDC: 734053; PDB: 1XFN).

**Data statement**
To foster transparency, we encourage you to state the availability of your data in your submission. This may be a requirement of your funding body or institution. If your data is unavailable to access or unsuitable to post, you will have the opportunity to indicate why during the submission process, for example by stating that the research data is confidential. The statement will appear with your published article on ScienceDirect. For more information, visit the Data Statement page.

**Submission Checklist**
The following list will be useful during the final checking of an article prior to sending it to the journal for review. Please consult this Guide for Authors for further details of any item.

**Ensure that the following items are present:**
One author has been designated as the corresponding author with contact details:
- E-mail address
- Full postal address
- Phone numbers
All necessary files have been uploaded, and contain:
- Keywords
- All figure captions
- All tables (including title, description, footnotes)
Further considerations
- Manuscript has been 'spell-checked' and 'grammar-checked'
- References are in the correct format for this journal
- All references mentioned in the Reference list are cited in the text, and vice versa
- Permission has been obtained for use of copyrighted material from other sources (including the Web)

For any further information please visit our customer support site at https://service.elsevier.com.

**AFTER ACCEPTANCE**

**Publication Charge**
An author is assessed ¥8,000 Japanese yen (¥5,000 Japanese yen when the corresponding author is a JSSX member) per page. The corresponding author will receive an invoice from JSSX after the galley proof is ready. An article is not published until the required payment is fully paid to JSSX. Invited articles are exempt from the publication charge. Charge may be modified without preliminary announcement.

**Use of the Digital Object Identifier**
The Digital Object Identifier (DOI) may be used to cite and link to electronic documents. The DOI consists of a unique alpha-numeric character string which is assigned to a document by the publisher upon the initial electronic publication. The assigned DOI never changes. Therefore, it is an ideal medium for citing a document, particularly 'Articles in press' because they have not yet received their full bibliographic information. When you use a DOI to create links to documents on the web, the DOIs are guaranteed never to change.

**Online proof correction**
To ensure a fast publication process of the article, we kindly ask authors to provide us with their proof corrections within two days. Corresponding authors will receive an e-mail with a link to our online proofing system, allowing annotation and correction of proofs online. The environment is similar to MS Word: in addition to editing text, you can also comment on figures/tables and answer questions from the Copy Editor. Web-based proofing provides a faster and less error-prone process by allowing you to directly type your corrections, eliminating the potential introduction of errors. If preferred, you can still choose to annotate and upload your edits on the PDF version. All instructions for proofing will be given in the e-mail we send to authors, including alternative methods to the online version and PDF.

We will do everything possible to get your article published quickly and accurately. Please use this proof only for checking the typesetting, editing, completeness and correctness of the text, tables and figures. Significant changes to the article as accepted for publication will only be considered at this
stage with permission from the Editor. It is important to ensure that all corrections are sent back to us in one communication. Please check carefully before replying, as inclusion of any subsequent corrections cannot be guaranteed. Proofreading is solely your responsibility.

**Offprints**
The corresponding author will, at no cost, receive a customized Share Link providing 50 days free access to the final published version of the article on ScienceDirect. The Share Link can be used for sharing the article via any communication channel, including email and social media. Corresponding authors who have published their article gold open access do not receive a Share Link as their final published version of the article is available open access on ScienceDirect and can be shared through the article DOI link.

**Author Inquiries**
For inquiries relating to the submission of articles (including electronic submission where available) please visit this journal’s homepage or contact the Editorial Office [dmpk.editorialoffice@elsevier.com]. You can track accepted articles at https://www.elsevier.com/trackarticle and set up e-mail alerts to inform you of when an article’s status has changed. Also accessible from here is information on copyright, frequently asked questions and more. Contact details for questions arising after acceptance of an article, especially those relating to proofs, will be provided by the publisher.

© Copyright 2018 Elsevier | https://www.elsevier.com